Inflammatory bowel disease
For certain infections, faecal transplants have resulted in remarkable recoveries. Will the same ever be true for people with inflammatory bowel disease (IBD)? It’s a condition on the rise in Asia, but why? Follow those trying to find out, and learn how our environments influence IBD in this new Outlook. Plus, an engaging infographic provides an introduction to the biology and statistics that underlie IBD.
For more on inflammatory bowel disease from nature.com, see: nature.com/subjects/inflammatory-bowel-disease
Free full access
Nature is pleased to acknowledge financial support from Salix Pharmaceuticals in producing this Outlook. The sponsor retains sole responsibility for the following messages.
Salix Pharmaceuticals is headquartered in Bridgewater, New Jersey and is a specialty pharmaceutical company committed to advancing the treatment of many chronic gastrointestinal disorders. For more than 20 years, Salix has licensed, developed, and marketed innovative products to provide healthcare professionals and patients solutions for the management of chronic and debilitating conditions. Salix currently markets its product line through dedicated, specialty sales groups to U.S. healthcare providers in the areas of gastroenterology, hepatology, internal medicine, primary care, and infectious disease.
For more information, please visit www.salix.com.
